RESUMEN
OBJECTIVE: Our aim was to measure the prevalence of delirium, its clinical features, and outcomes in older patients referred to a memory clinic. METHODS: A retrospective cohort study of 109 older outpatients with delirium referred to a memory clinic with a home care service. Delirium was diagnosed using the confusion assessment method and dementia with the DSM-5 criteria. We collected information on cognitive and functional status, mortality, institutionalization, and hospitalization during 6 months following the delirium episode. RESULTS: Delirium prevalence was 3.6%, mostly of hyperactive type. Delirium worsened functional (ADL 2.95 ± 1.95 vs. 2.16 ± 1.84) and cognitive (MMSE 13.88 ± 8.96 vs.11.0 ± 9.49) status after 6 months compared to the baseline. The mortality rate was 29.4%, and 28.3% were admitted to a long-term facility after the episode of delirium. Of these patients, more than half were hospitalized during the follow-up. Of the 109 patients with delirium, 85 were managed at home and 24 were hospitalized. Patients who were hospitalized had more severe behavioral symptoms during the delirium episode. There was no difference in mortality and institutionalization according to the home or hospital management. CONCLUSIONS: This retrospective cohort study adds novel information to the existing literature of an understudied setting and population. The study supports the need to further investigate the feasibility and efficacy of the hospital at home models for the prevention and management of delirium in a high-risk population.
Asunto(s)
Delirio , Demencia , Anciano , Delirio/diagnóstico , Delirio/epidemiología , Delirio/terapia , Demencia/epidemiología , Hospitalización , Humanos , Vida Independiente , Prevalencia , Estudios RetrospectivosRESUMEN
High-dose, intravenous methylprednisolone (MP) is the only recommended first-line treatment for multiple sclerosis relapses. However, there are increasing reports on liver toxicity induced by this treatment regimen. We report of 4 multiple sclerosis patients with no history of viral/metabolic liver disorders or alcohol/hepatotoxic drug intake, who developed hypertransaminasaemia following intravenous MP. In 2 of the patients, liver biopsy showed periportal fibrosis, piecemeal necrosis, and inflammatory cell infiltrates. A rechallenge test confirmed a causal association in 1 case. MP-induced liver toxicity may be more frequent than commonly thought and it is important to report this adverse reaction, which is potentially lethal, and to raise awareness on the potential hepatotoxicity of corticosteroid pulses.
Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/diagnóstico , Metilprednisolona/administración & dosificación , Metilprednisolona/efectos adversos , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Administración Intravenosa , Adulto , Femenino , Humanos , Persona de Mediana Edad , Quimioterapia por Pulso , Adulto JovenAsunto(s)
Anemia/etiología , Anticuerpos Monoclonales Humanizados/efectos adversos , Inmunosupresores/efectos adversos , Esclerosis Múltiple Recurrente-Remitente/tratamiento farmacológico , Anemia/patología , Anemia/terapia , Anticuerpos Monoclonales Humanizados/uso terapéutico , Transfusión Sanguínea , Médula Ósea/patología , Femenino , Estudios de Seguimiento , Humanos , Inmunosupresores/uso terapéutico , Integrina alfa1beta1/antagonistas & inhibidores , Persona de Mediana Edad , Esclerosis Múltiple Recurrente-Remitente/complicaciones , NatalizumabRESUMEN
We reviewed the records of 391 patients who had presented with a Clinically Isolated Syndrome and selected 205 who had performed a baseline spinal tap and MRI scan. We studied cerebrospinal fluid (CSF) and serum IgM oligoclonal bands (IgMOB) using agarose gel isoelectric focusing and analyzed the impact of baseline clinical, MRI and CSF variables on the risk of conversion to clinically definite multiple sclerosis, i.e. on the risk of a clinical relapse. At survival analysis, a lower age at onset, an onset with optic neuritis and the presence of CSF-restricted IgMOB increased the risk of a relapse. Only the presence of CSF-restricted IgMOB predicted a relapse within one year.